Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADVC006
- Development stage
- Preclinical
- Lead developer
- Advancell
- Modality
- Small Molecules
01
Overview
ADVC006 is a chemical drug candidate developed by AdvanCell Isotopes. It is in preclinical development for the treatment of various cancers, including bladder cancer, colorectal cancer, hereditary renal cancer associated 1, and pancreatic cancer. The specific mechanism of action and molecular targets have not been disclosed publicly as of the latest available information. The drug is being investigated primarily within oncology and related therapeutic areas such as neoplasms, digestive system disorders, and endocrinology/metabolic diseases[1][3].
- Brand names
- ADVC006ADVC-006ADVC 006
- Other names
- ADVC006ADVC-006ADVC 006
Beyond the preview
Go deeper on ADVC006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADVC006.